Palatin pummelled as dry eye therapy underwhelms in phase 3 February 29, 2024 AutoBot News 0 Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.